5 November 2026
Morgan Advanced Materials plc
Notification of transactions of Directors/Persons Discharging Managerial Responsibilities
1 | Details of the person discharging managerial responsibilities / persons closely associated | |||||
a) | Name | Laurent Cohen-Scali | ||||
2 | Reason for the notification | |||||
a) | Position/status | PDMR - President, Thermal Products | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Morgan Advanced Materials Plc | ||||
b) | LEI | I4K14LL95N2PHDL7EG85 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 25p each GB0006027295 | ||||
b) | Nature of the transaction | Sale of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A | ||||
e) | Date of the transaction | 2026-11-05 | ||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||
This notice is given in fulfilment of the obligation under Article 19 of the Market Abuse Regulation.
For further enquiries, please contact:
Win Chime
Morgan Advanced Materials plc
Company.secretariat@morganplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.